Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru


ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Астма и Аллергия
2022 / N 2

COVID-19: конец пандемии?
С.Ю. Чикина

Список литературы

1. Koelle K, Martin MA, Antia R, Lopman B, Dean NE. The changing epidemiology of SARS-CoV-2. Science (New York, N.Y.) 2022 Mar;375(6585):1116-21.
2. El-Shabasy RM, Nayel MA, Taher MM, Abdelmonem R, Shoueir KR, Kenawy ER. Three waves changes, new variant strains, and vaccination effect against COVID-19 pandemic. International Journal of Biological Macromolecules 2022 Apr;204:161-8.
3. Jia Z, Gong W. Will mutations in the spike protein of SARS-CoV-2 lead to the failure of COVID-19 vaccines? Journal of Korean Medical Science 2021 May;36(18):e124.
4. Billah MA, Miah MM, Khan MN. Reproductive number of coronavirus: a systematic review and meta-analysis based on global level evidence. PLoS One 2020 Nov 11;15(11):e0242128.
5. Ren SY, Wang WB, Gao RD, Zhou AM. Omicron variant (B.1.1.529) of SARS-CoV-2: mutation, infectivity, transmission, and vaccine resistance. World Journal of Clinical Cases 2022 Jan;10(1):1-11.
6. Zhang M. Omicron now accounts for 3% of US coronavirus cases. China Daily Global. Updated 15 Dec 2021. Available from: https://global.chinadaily.com.cn/a/202112/15/WS61b95f63a310cdd39bc7b7f8.html Accessed 2022 Sep 19.
7. Tanaka H, Ogata T, Shibata T, Nagai H, Takahashi Y, Kinoshita M, Matsubayashi K, Hattori S, Taniguchi C. Shorter incubation period among COVID-19 cases with the BA.1 Omicron variant. International Journal of Environmental Research and Public Health 2022 May;19(10):6330.
8. Wang Y, Chen R, Hu F, Lan Y, Yang Z, Zhan C, Shi J, Deng X, Jiang M, Zhong S, Liao B, Deng K, Tang J, Guo L, Jiang M, Fan Q, Li M, Liu J, Shi Y, Deng X, Xiao X, Kang M, Li Y, Guan W, Li Y, Li S, Li F, Zhong N, Tang X. Transmission, viral kinetics and clinical characteristics of the emergent SARS-CoV-2 Delta VOC in Guangzhou, China. EClinicalMedicine 2021 Oct;40:101129.
9. Ulloa AC, Buchan SA, Daneman N, Brown KA. Estimates of SARS-CoV-2 Omicron variant severity in Ontario, Canada. JAMA 2022 Apr;327(13):1286-8.
10. Wolter N, Jassat W, Walaza S, Welch R, Moultrie H, Groome M, Amoako DG, Everatt J, Bhiman JN, Scheepers C, Tebeila N, Chiwandire N, du Plessis M, Govender N, Ismail A, Glass A, Mlisana K, Stevens W, Treurnicht FK, Makatini Z, Hsiao NY, Parboosing R, Wadula J, Hussey H, Davies MA, Boulle A, von Gottberg A, Cohen C. Early assessment of the clinical severity of the SARS-CoV-2 Omicron variant in South Africa: a data linkage study. The Lancet. 2022 Jan;399(10323):437-46.
11. Weishampel ZA, Young J, Fischl M, Fischer RJ, Donkor IO, Riopelle JC, Schulz JE, Port JR, Saturday TA, van Doremalen N, Berry JD, Munster VJ, Yinda CK. OraSure InteliSwab™ Rapid Antigen Test performance with the SARS-CoV-2 variants of concern-Alpha, Beta, Gamma, Delta, and Omicron. Viruses 2022 Mar;14(3):543.
12. Deerain J, Druce J, Tran T, Batty M, Yoga Y, Fennell M, Dwyer DE, Kok J, Williamson DA. Assessment of the analytical sensitivity of 10 lateral flow devices against the SARS-CoV-2 Omicron variant. Journal of Clinical Microbiology 2022 Feb;60(2):e0247921.
13. Mahase E. Covid-19: UK approves Pfizer and BioNTech vaccine with rollout due to start next week. BMJ 2020 Dec;371:m4714.
14. Anesi J. The Advisory Committee on Immunization Practices’ updated interim recommendation for allocation of COVID-19 vaccine – United States, December 2020. American Journal of Transplantation 2021 Feb;21(2):897.
15. Palacios R, Patiño EG, de Oliveira Piorelli R, Conde MTRP, Batista AP, Zeng G, Xin Q, Kallas EG, Flores J, Ockenhouse CF, Gast C. Double-blind, randomized, placebo-controlled Phase III clinical trial to evaluate the efficacy and safety of treating healthcare professionals with the adsorbed COVID-19 (inactivated) vaccine manufactured by Sinovac – PROFISCOV: a structured summary of a study protocol for a randomised controlled trial. Trials 2020 Oct;21(1):853.
16. Logunov DY, Dolzhikova IV, Zubkova OV, Tukhvatullin AI, Shcheblyakov DV, Dzharullaeva AS, Grousova DM, Erokhova AS, Kovyrshina AV, Botikov AG, Izhaeva FM, Popova O, Ozharovskaya TA, Esmagambetov IB, Favorskaya IA, Zrelkin DI, Voronina DV, Shcherbinin DN, Semikhin AS, Simakova YV, Tokarskaya EA, Lubenets NL, Egorova DA, Shmarov MM, Nikitenko NA, Morozova LF, Smolyarchuk EA, Kryukov EV, Babira VF, Borisevich SV, Naroditsky BS, Gintsburg AL. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. The Lancet 2020 Sep;396(10255):887-97.
17. Voysey M, Costa Clemens SA, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE, Bibi S, Briner C, Cicconi P, Clutterbuck EA, Collins AM, Cutland CL, Darton TC, Dheda K, Dold C, Duncan CJA, Emary KRW, Ewer KJ, Flaxman A, Fairlie L, Faust SN, Feng S, Ferreira DM, Finn A, Galiza E, Goodman AL, Green CM, Green CA, Greenland M, Hill C, Hill HC, Hirsch I, Izu A, Jenkin D, Joe CCD, Kerridge S, Koen A, Kwatra G, Lazarus R, Libri V, Lillie PJ, Marchevsky NG, Marshall RP, Mendes AVA, Milan EP, Minassian AM, McGregor A, Mujadidi YF, Nana A, Padayachee SD, Phillips DJ, Pittella A, Plested E, Pollock KM, Ramasamy MN, Ritchie AJ, Robinson H, Schwarzbold AV, Smith A, Song R, Snape MD, Sprinz E, Sutherland RK, Thomson EC, Török ME, Toshner M, Turner DPJ, Vekemans J, Villafana TL, White T, Williams CJ, Douglas AD, Hill AVS, Lambe T, Gilbert SC, Pollard AJ; Oxford COVID Vaccine Trial Group. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. The Lancet 2021 Mar;397(10277):881-91.
18. Lumley SF, O’Donnell D, Stoesser NE, Matthews PC, Howarth A, Hatch SB, Marsden BD, Cox S, James T, Warren F, Peck LJ, Ritter TG, de Toledo Z, Warren L, Axten D, Cornall RJ, Jones EY, Stuart DI, Screaton G, Ebner D, Hoosdally S, Chand M, Crook DW, O’Donnell AM, Conlon CP, Pouwels KB, Walker AS, Peto TEA, Hopkins S, Walker TM, Jeffery K, Eyre DW; Oxford University Hospitals Staff Testing Group. Antibody status and incidence of SARS-CoV-2 infection in health care workers. The New England Journal of Medicine 2021 Feb;384(6):533-40.
19. Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, McGettigan J, Khetan S, Segall N, Solis J, Brosz A, Fierro C, Schwartz H, Neuzil K, Corey L, Gilbert P, Janes H, Follmann D, Marovich M, Mascola J, Polakowski L, Ledgerwood J, Graham BS, Bennett H, Pajon R, Knightly C, Leav B, Deng W, Zhou H, Han S, Ivarsson M, Miller J, Zaks T; COVE Study Group. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. The New England Journal of Medicine 2021 Feb;384(5):403-16.
20. Public Health England. SARS-CoV-2 variants of concern and variants under investigation in England. Update 17 Sep 2021. Available at: https://www.gov.uk/government/publications/investigation-of-novel-sars-cov-2-variant-variant-of-concern-20201201 Accessed 2022 Sep 19.
21. Accorsi EK, Britton A, Fleming-Dutra KE, Smith ZR, Shang N, Derado G, Miller J, Schrag SJ, Verani JR. Association between 3 doses of mRNA COVID-19 vaccine and symptomatic infection caused by the SARS-CoV-2 Omicron and Delta variants. JAMA 2022 Feb;327(7):639-51.
22. Zeng C, Evans JP, Qu P, Faraone J, Zheng YM, Carlin C, Bednash JS, Zhou T, Lozanski G, Mallampalli R, Saif LJ, Oltz EM, Mohler P, Xu K, Gumina RJ, Liu SL. Neutralization and stability of SARS-CoV-2 Omicron variant. bioRxiv 2021.12.16.472934; doi: 10.1101/2021.12.16.472934.
23. Doria-Rose NA, Shen X, Schmidt SD, O’Dell S, McDanal C, Feng W, Tong J, Eaton A, Maglinao M, Tang H, Manning KE, Edara VV, Lai L, Ellis M, Moore K, Floyd K, Foster SL, Atmar RL, Lyke KE, Zhou T, Wang L, Zhang Y, Gaudinski MR, Black WP, Gordon I, Guech M, Ledgerwood JE, Misasi JN, Widge A, Roberts PC, Beigel J, Korber B, Pajon R, Mascola JR, Suthar MS, Montefiori DC. Booster of mRNA-1273 strengthens SARS-CoV-2 Omicron neutralization. medRxiv 2021.12.15.21267805; doi: 10.1101/2021.12.15.21267805.
24. Evans JP, Zeng C, Carlin C, Lozanski G, Saif LJ, Oltz EM, Gumina RJ, Liu SL. Neutralizing antibody responses elicited by SARS-CoV-2 mRNA vaccination wane over time and are boosted by breakthrough infection. Science Translational Medicine 2022 Mar;14(637):eabn8057.
25. Regev-Yochay G, Gonen T, Gilboa M, Mandelboim M, Indenbaum V, Amit S, Meltzer L, Asraf K, Cohen C, Fluss R, Biber A, Nemet I, Kliker L, Joseph G, Doolman R, Mendelson E, Freedman LS, Harats D, Kreiss Y, Lustig Y. 4th dose COVID mRNA vaccines’ immunogenicity & efficacy against Omicron VOC. medRxiv 2022.02.15.22270948; doi: 10.1101/2022.02.15.22270948.
26. Xiang Y, Jia Y, Chen L, Guo L, Shu B, Long E. COVID-19 epidemic prediction and the impact of public health interventions: a review of COVID-19 epidemic models. Infectious Diseases Modeling 2021;6:324-42.
27. Kucharski AJ, Russell TW, Diamond C, Liu Y, Edmunds J, Funk S, Eggo RM; Centre for Mathematical Modelling of Infectious Diseases COVID-19 working group. Early dynamics of transmission and control of COVID-19: a mathematical modelling study. The Lancet. Infectious Diseases 2020 May;20(5):553-8.
28. Dutta A. COVID-19 waves: variant dynamics and control. Science Reports 2022 Jun;12(1):9332.
  

[ Содержание выпуска N 2 | Выпуски журнала | Список журналов ]